Table 1:
Intention to Treat Patient, Disease, and Treatment Characteristics by Treatment Arm
| 70 Gy Arm | 78 Gy Arm | |
|---|---|---|
| Total number of patients | 150 | 151 |
| Median Age at Diagnosis (range), y | 69 (50-79) | 69 (48-81) |
| Race | ||
| White | 124 (82.7%) | 132 (86.1%) |
| Black | 16 (10.7%) | 12 (7.9%) |
| Hispanic | 7 (4.7%) | 4 (2.7%) |
| Asian | 3 (2%) | 3 (2%) |
| Median Pre-Treatment PSA, (range), ng/mL | 7.50 (1.1 – 32.5) | 7.80 (0.6 – 86.1) |
| Pre-T reatment PSA Grouping, ng/mL | ||
| ≤10 | 98 (65.3%) | 98 (64.9%) |
| 10 - 20 | 42 (28%) | 47 (31.1%) |
| >20 | 10 (6.7%) | 6 (4%) |
| Gleason Total | ||
| <6 | 13 (8.7%) | 15 (9.9%) |
| 6 | 57 (38%) | 59 (39.1%) |
| 7 | 54 (36%) | 50 (33.1%) |
| 8 | 19 (12.7%) | 22 (14.6%) |
| 9 | 5 (3.3%) | 5 (3.3%) |
| 10 | 2 (1.3%) | 0 |
| AJCC Tumor Stage | ||
| T1 | 45 (30%) | 43 (28.5%) |
| T2 | 79 (52.7%) | 74 (49%) |
| T3 | 26 (17.3%) | 34 (22.5%) |
| NCCN Risk Group | ||
| Low | 31 (20.7%) | 31 (20.5%) |
| Intermediate | 71 (47.3%) | 67 (44.4%) |
| High | 48 (32%) | 53 (35.1%) |
| Lost to Follow-up | 8 (5.3%) | 14 (9.3%) |
Prostate-specific antigen (PSA); American Joint Commission on Cancer (AJCC); National Comprehensive Care Network (NCCN); Gray (Gy)